{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T04:42:10Z","timestamp":1790224930441,"version":"4.1.0"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,10]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Marfan syndrome (MFS) is the most common cause of aortic aneurysm in children and is associated with premature mortality. Whereas surgical therapy remains the primary treatment to prevent aortic complications, medical therapy may slow or prevent aortic growth. Pediatricians and pediatric cardiologists should become familiar with the diagnosis and management of MFS. This review focuses on the medical management for the most important life-threatening manifestation of MFS, thoracic aortic disease.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Several large-scale clinical trials and one meta-analysis have been reported comparing angiotensin receptors blockers with the standard therapy, beta blockers.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>From the assembled evidence described in this review, beta blockers and angiotensin receptors blockers show clinical equivalence and either class of agent may be an appropriate choice for the medical management of aortic growth in children with MFS.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mop.0000000000000671","type":"journal-article","created":{"date-parts":[[2018,7,23]],"date-time":"2018-07-23T10:25:20Z","timestamp":1532341520000},"page":"639-644","source":"Crossref","is-referenced-by-count":6,"title":["Medical management of aortic disease in children with Marfan syndrome"],"prefix":"10.1097","volume":"30","author":[{"given":"Mark E.","family":"Lindsay","sequence":"first","affiliation":[{"name":"Massachusetts General Hospital Thoracic Aortic Center"},{"name":"Division of Cardiology"},{"name":"Pediatric Cardiology, Departments of Medicine and Pediatrics, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20231002","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1161\/01.CIR.11.3.321","article-title":"The cardiovascular aspects of Marfan's syndrome: a heritable disorder of connective tissue","volume":"11","author":"McKusick","year":"1955","journal-title":"Circulation"},{"key":"R2-20231002","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S0003-4975(01)03336-7","article-title":"Aortic root replacement in 271 Marfan patients: a 24-year experience","volume":"73","author":"Gott","year":"2002","journal-title":"Ann Thorac Surg"},{"key":"R3-20231002","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1056\/NEJM199904293401702","article-title":"Replacement of the aortic root in patients with Marfan's syndrome","volume":"340","author":"Gott","year":"1999","journal-title":"N Engl J Med"},{"key":"R4-20231002","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1136\/jmg.2009.072785","article-title":"The revised Ghent nosology for the Marfan syndrome","volume":"47","author":"Loeys","year":"2010","journal-title":"J Med Genet"},{"key":"R5-20231002","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1056\/NEJMoa055695","article-title":"Aneurysm syndromes caused by mutations in the TGF-beta receptor","volume":"355","author":"Loeys","year":"2006","journal-title":"N Engl J Med"},{"key":"R6-20231002","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1016\/j.jacc.2010.02.015","article-title":"2010\u200aACCF\/AHA\/AATS\/ACR\/ASA\/SCA\/SCAI\/SIR\/STS\/SVM Guidelines for the diagnosis and management of patients with thoracic aortic disease. A Report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine","volume":"55","author":"Hiratzka","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"R7-20231002","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1016\/j.jacc.2015.09.039","article-title":"Eligibility and disqualification recommendations for competitive athletes with cardiovascular abnormalities: task force 7: aortic diseases, including Marfan syndrome: a scientific statement from the American Heart Association and American College of Cardiology","volume":"66","author":"Braverman","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"R8-20231002","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1056\/NEJM199405123301902","article-title":"Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan's syndrome","volume":"330","author":"Shores","year":"1994","journal-title":"N Engl J Med"},{"key":"R9-20231002","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.amjcard.2006.08.048","article-title":"Effect of beta-blockade on ascending aortic dilatation in children with the Marfan syndrome","volume":"99","author":"Ladouceur","year":"2007","journal-title":"Am J Cardiol"},{"key":"R10-20231002","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1126\/science.1124287","article-title":"Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome","volume":"312","author":"Habashi","year":"2006","journal-title":"Science"},{"key":"R11-20231002","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1056\/NEJMoa0706585","article-title":"Angiotensin II blockade and aortic-root dilation in Marfan's syndrome","volume":"358","author":"Brooke","year":"2008","journal-title":"N Engl J Med"},{"key":"R12-20231002","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.mayocp.2012.11.005","article-title":"Losartan added to beta-blockade therapy for aortic root dilation in Marfan syndrome: a randomized, open-label pilot study","volume":"88","author":"Chiu","year":"2013","journal-title":"Mayo Clin Proc"},{"key":"R13-20231002","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1093\/eurheartj\/eht334","article-title":"Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial","volume":"34","author":"Groenink","year":"2013","journal-title":"Eur Heart J"},{"key":"R14-20231002","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1093\/eurheartj\/ehv151","article-title":"Marfan Sartan: a randomized, double-blind, placebo-controlled trial","volume":"36","author":"Milleron","year":"2015","journal-title":"Eur Heart J"},{"key":"R15-20231002","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1093\/eurheartj\/ehv575","article-title":"Efficacy of losartan vs. atenolol for the prevention of aortic dilation in Marfan syndrome: a randomized clinical trial","volume":"37","author":"Forteza","year":"2016","journal-title":"Eur Heart J"},{"key":"R16-20231002","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1056\/NEJMoa1404731","article-title":"Atenolol versus losartan in children and young adults with Marfan's syndrome","volume":"371","author":"Lacro","year":"2014","journal-title":"N Engl J Med"},{"key":"R17-20231002","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ijcard.2016.04.186","article-title":"The effect of losartan on progressive aortic dilatation in patients with Marfan's syndrome: a meta-analysis of prospective randomized clinical trials","volume":"217","author":"Gao","year":"2016","journal-title":"Int J Cardiol"},{"key":"R18-20231002","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(17)32714-9","article-title":"Percutaneous coronary intervention in stable angina (ORBITA): a double-blind, randomised controlled trial","volume":"391","author":"Al-Lamee","year":"2018","journal-title":"Lancet"}],"container-title":["Current Opinion in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00008480-201810000-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T19:20:27Z","timestamp":1696274427000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00008480-201810000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/mop.0000000000000671","relation":{},"ISSN":["1040-8703","1531-698X"],"issn-type":[{"value":"1040-8703","type":"print"},{"value":"1531-698X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10]]}}}